Turning Point Therapeutics, Inc.
(NASDAQ : TPTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.78%33.770.9%$1154.74m
JNJJohnson & Johnson -0.37%142.320.7%$1080.84m
BMYBristol-Myers Squibb Co. -0.34%60.091.0%$981.80m
MRKMerck & Co., Inc. -0.48%78.350.7%$827.25m
ABBVAbbVie, Inc. 0.45%99.801.9%$791.34m
LLYEli Lilly & Co. 0.80%168.091.1%$701.95m
AZNAstraZeneca Plc 1.52%54.281.2%$299.61m
VXRTVaxart, Inc. -6.76%8.270.0%$279.73m
RPRXRoyalty Pharma Plc 2.61%48.280.1%$239.55m
NVSNovartis AG -0.13%87.690.2%$155.31m
RGENRepligen Corp. 0.54%124.817.1%$118.35m
GSKGlaxoSmithKline Plc 0.47%40.570.2%$117.97m
NVONovo Nordisk A/S 1.00%65.710.1%$95.42m
RETAReata Pharmaceuticals, Inc. 0.07%155.753.4%$81.80m
SNYSanofi 0.02%51.440.2%$73.82m

Company Profile

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.